{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:44Z","timestamp":1740108164636,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-021-04847-9","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:10:51Z","timestamp":1625472651000},"page":"700-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bedarf von Real-World-klinischen Therapiestudien f\u00fcr die Hidradenitis suppurativa\/Acne inversa","Need for real-world data studies on hidradenitis suppurativa\/acne inversa treatment"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"C. C.","family":"Zouboulis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"4847_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.17151","volume":"180","author":"M Argyropoulou","year":"2019","unstructured":"Argyropoulou\u00a0M, Kanni\u00a0T, Kyprianou\u00a0M, Melachroinopoulos\u00a0N, Giamarellos-Bourboulis\u00a0EJ (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a\u00a0retrospective analysis of a\u00a0real-world cohort. Br J Dermatol 180:1161\u20131168","journal-title":"Br J Dermatol"},{"issue":"Suppl 6","key":"4847_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.15826","volume":"33","author":"V Bettoli","year":"2019","unstructured":"Bettoli\u00a0V, Cazzaniga\u00a0S, Scuderi\u00a0V et\u00a0al (2019) Hidradenitis suppurativa epidemiology: from the first Italian registry in 2009 to the most recent epidemiology updates\u2014Italian Registry Hidradenitis Suppurativa project 2. J\u00a0Eur Acad Dermatol Venereol 33(Suppl 6):4\u20136","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4847_CR3","first-page":"770","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner\u00a0D, Rubin\u00a0DT, Mease\u00a0P et\u00a0al (2019) Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J\u00a0Manag Care Spec Pharm 25:770\u2013779","journal-title":"J Manag Care Spec Pharm"},{"key":"4847_CR4","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.21.06966-8","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro\u00a0RD, Chiricozzi\u00a0A et\u00a0al (2021) Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Ital J Dermatol Venerol. https:\/\/doi.org\/10.23736\/S2784-8671.21.06966-8","journal-title":"Ital J Dermatol Venerol"},{"key":"4847_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave\u00a0A, Kurz\u00a0X, Arlett\u00a0P (2019) Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther 106:36","journal-title":"Clin Pharmacol Ther"},{"key":"4847_CR6","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1111\/jdv.15050","volume":"32","author":"S Cazzaniga","year":"2018","unstructured":"Cazzaniga\u00a0S, Naldi\u00a0L, Damiani\u00a0G et al (2018) Validation of a\u00a0visual-aided questionnaire for the self-assessment of hidradenitits suppurativa. J\u00a0Eur Acad Dermatol Venereol 32:1993\u20131998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4847_CR7","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jaad.2021.02.075","volume":"85","author":"S Cazzaniga","year":"2021","unstructured":"Cazzaniga\u00a0S, Pezzolo\u00a0E, Garcovich\u00a0S, Naldi\u00a0L, IRHIS Study Group (2021) Late-onset hidradenitis suppurativa: a\u00a0cluster analysis of the National Italian Registry IRHIS. J\u00a0Am Acad Dermatol 85:e29\u2013e32","journal-title":"J Am Acad Dermatol"},{"key":"4847_CR8","doi-asserted-by":"publisher","first-page":"adv00172","DOI":"10.2340\/00015555-3520","volume":"100","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi\u00a0A, Giovanardi\u00a0G, Garcovich\u00a0S et al (2020) Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: a real-life monocentric experience. Acta Derm Venereol 100:adv172","journal-title":"Acta Derm Venereol"},{"key":"4847_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1212\/CPJ.0000000000000501","volume":"8","author":"JR Corboy","year":"2018","unstructured":"Corboy\u00a0JR (2018) Real-world practice. Neurol Clin Pract 8:275","journal-title":"Neurol Clin Pract"},{"key":"4847_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","volume":"27","author":"M Delobeau","year":"2016","unstructured":"Delobeau\u00a0M, Abdou\u00a0A, Puzenat\u00a0E et al (2016) Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. J\u00a0Dermatolog Treat 27:251\u2013253","journal-title":"J Dermatolog Treat"},{"key":"4847_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cpt.1638","volume":"107","author":"HG Eichler","year":"2020","unstructured":"Eichler\u00a0HG, Koenig\u00a0F, Arlett\u00a0P et al (2020) Are novel, nonrandomised analytic methods fit for decision-making? The need for prospective, controlled, and transparent validation. Clin Pharmacol Ther 107:773\u2013779","journal-title":"Clin Pharmacol Ther"},{"key":"4847_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias\u00a0MH, Johnston\u00a0AD, Kutner\u00a0AJ, Micheletti\u00a0RG, Hosgood\u00a0HD, Cohen\u00a0SR (2020) High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J\u00a0Am Acad Dermatol 82:1094\u20131101","journal-title":"J Am Acad Dermatol"},{"key":"4847_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677","author":"A Jfri","year":"2021","unstructured":"Jfri\u00a0A, Nassim\u00a0D, O\u2019Brien\u00a0E, Gulliver\u00a0W, Nikolakis\u00a0G, Zouboulis\u00a0CC (2021) Prevalence of hidradenitis suppurativa: a systematic review and meta-regression study. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1677","journal-title":"JAMA Dermatol"},{"key":"4847_CR14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaad.2020.12.012","volume":"84","author":"H Khosravi","year":"2021","unstructured":"Khosravi\u00a0H, Anderson\u00a0AM, Kettering\u00a0C, Mizes\u00a0A, Patton\u00a0T (2021) Real-world experience of adalimumab in the treatment of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 84:1406\u20131409","journal-title":"J Am Acad Dermatol"},{"key":"4847_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clindermatol.2016.10.018","volume":"35","author":"RK Kj\u00e6rsgaard Andersen","year":"2017","unstructured":"Kj\u00e6rsgaard Andersen\u00a0RK, Jemec\u00a0GB (2017) Treatments for hidradenitis suppurativa. Clin Dermatol 35:218\u2013224","journal-title":"Clin Dermatol"},{"key":"4847_CR16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/jdv.16132","volume":"34","author":"AB Kimball","year":"2020","unstructured":"Kimball\u00a0AB, Crowley\u00a0JJ, Papp\u00a0K et al (2020) Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. J\u00a0Eur Acad Dermatol Venereol 34:1302\u20131308","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4847_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball\u00a0AB, Okun\u00a0MM, Williams\u00a0DA et\u00a0al (2016) Two phase 3 trials of adalimumab treatment of hidradenitis suppurativa. N\u00a0Engl J Med 375:422\u2013434","journal-title":"N Engl J Med"},{"key":"4847_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","volume":"5","author":"C Marasca","year":"2019","unstructured":"Marasca\u00a0C, Megna\u00a0M, Balato\u00a0A, Balato\u00a0N, Napolitano\u00a0M, Fabbrocini\u00a0G (2019) Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep 5:184\u2013187","journal-title":"JAAD Case Rep"},{"key":"4847_CR19","doi-asserted-by":"publisher","first-page":"e030579","DOI":"10.1136\/bmjopen-2019-030579","volume":"9","author":"J Marvel","year":"2019","unstructured":"Marvel\u00a0J, Vlahiotis\u00a0A, Sainski-Nguyen\u00a0A, Willson\u00a0T, Kimball\u00a0A (2019) Disease burden and cost of hidradenitis suppurativa: a\u00a0retrospective examination of US administrative claims data. BMJ Open 9:e30579","journal-title":"BMJ Open"},{"key":"4847_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano\u00a0AV, Genovese\u00a0G, Casazza\u00a0G et al (2021) Evidence for a\u00a0\u201ewindow of opportunity\u201c in hidradenitis suppurativa treated with adalimumab: a\u00a0retrospective, real-life multicenter cohort study. Br J Dermatol 184:133\u2013140","journal-title":"Br J Dermatol"},{"key":"4847_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12916-016-0647-x","volume":"14","author":"L McDonald","year":"2016","unstructured":"McDonald\u00a0L, Lambrelli\u00a0D, Wasiak\u00a0R, Ramagopalan\u00a0SV (2016) Real-world data in the United Kingdom: opportunities and challenges. BMC Med 14:97","journal-title":"BMC Med"},{"key":"4847_CR22","doi-asserted-by":"crossref","unstructured":"Nikolakis G, Kristandt A, Hauptmann M, Becker M, Zouboulis CC (2021) Short-term intravenous clindamycin enhances the benefit of oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case-series. Br J Dermatol (in press)","DOI":"10.1111\/bjd.20645"},{"key":"4847_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000507323","volume":"236","author":"LAV Orenstein","year":"2020","unstructured":"Orenstein\u00a0LAV, Nguyen\u00a0TV, Damiani\u00a0G, Sayed\u00a0C, Jemec\u00a0GBE, Hamzavi\u00a0I (2020) Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology 236:393\u2013412","journal-title":"Dermatology"},{"key":"4847_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20525","author":"EM S\u00e1nchez Mart\u00ednez","year":"2021","unstructured":"S\u00e1nchez Mart\u00ednez\u00a0EM, Murray\u00a0G, Alfageme Rold\u00e1n\u00a0F, Garc\u00eda Ruiz\u00a0R, Tobin\u00a0AM, Zouboulis\u00a0CC (2021) Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicenter study. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.20525","journal-title":"Br J Dermatol"},{"key":"4847_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos\u00a0T, Yang\u00a0H, Mu\u00a0F, Calimlim\u00a0B, Signorovitch\u00a0J (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147\u2013514","journal-title":"Br J Dermatol"},{"key":"4847_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos\u00a0T, Zouboulis\u00a0CC (2020) Review of comorbidities of hidradenitis suppurativa: Implications for daily clinical practice. Dermatol Ther (Heidelb) 10:63\u201371 (Erratum: 2020;10:523)","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4847_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.089","author":"KR van Straalen","year":"2021","unstructured":"van Straalen\u00a0KR, Tzellos\u00a0T, Guillem\u00a0P et\u00a0al (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa; results of a\u00a0prospective European cohort study. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.089","journal-title":"J Am Acad Dermatol"},{"key":"4847_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.19165","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC (2021) First real-world data provides evidence for a\u00a0\u201ewindow of opportunity\u201c in hidradenitis suppurativa\/acne inversa treatment. Br J Dermatol 184:10\u201311","journal-title":"Br J Dermatol"},{"issue":"Suppl 5","key":"4847_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.08006.x","volume":"10","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K et al (2012) S1 \u2013 Leitlinie zur Therapie der Hidradenitis suppurativa\/Acne inversa (ICD-10 Ziffer: L73.2). J\u00a0Dtsch Dermatol Ges 10(Suppl 5):S1\u2013S31","journal-title":"J Dtsch Dermatol Ges"},{"key":"4847_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000503606","volume":"236","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis\u00a0CC, Hansen\u00a0H, Caposiena Caro\u00a0RD et\u00a0al (2020) Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa. Dermatology 236:25\u201330","journal-title":"Dermatology"},{"key":"4847_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis\u00a0CC, Tzellos\u00a0T, Kyrgidis\u00a0A et\u00a0al (2017) Development and validation of IHS4, a\u00a0novel dynamic scoring system to assess hidradenitis suppurativa\/acne inversa severity. Br J Dermatol 177:1401\u20131409","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04847-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:04:24Z","timestamp":1627542264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04847-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4847"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04847-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"type":"print","value":"0017-8470"},{"type":"electronic","value":"1432-1173"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"25 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.C.\u00a0Zouboulis hat Berater- und Vortragshonorare von Idorsia, Incyte, InflaRx, Janssen, Novartis, Regeneron und UCB erhalten, die nicht mit diesem Manuskript in Verbindung stehen. Seine Abteilung erhielt Honorare von AbbVie, InflaRx, Novartis und UCB f\u00fcr seine Teilnahme an klinischen Studien. E.\u00a0von Stebut hat Berater- und Vortragshonorare von Almirall, InfectoPharm, Janssen, Leo Pharma und Novartis erhalten, die nicht mit diesem Manuskript in Verbindung stehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}